What is the current stock price of Caribou Biosciences, Inc. (CRBU)?

As of the latest market data, Caribou Biosciences, Inc. (CRBU) is trading at $1.93. The stock has seen a loss of -1.53% today.

Does Caribou Biosciences, Inc. (CRBU) pay a dividend?

Based on current data, Caribou Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Caribou Biosciences, Inc.?

The current market capitalization of Caribou Biosciences, Inc. (CRBU) is approximately unavailable.

CRBU

Caribou Biosciences, Inc.·Healthcare

1.93

1.531%(−0.03)

Market Closed

1.99

3.109%(+0.06)

After Hours

Last Updated: — ET

52W L: $0.7152W H: $3.54

CRBU NEWS

globenewswire.com

Mar 31

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r MM patient cohort -- -- Ongoing dose expansion enrollment in CaMMouflage phase 1 clinical trial includes BCMA-naïve and BCMA-exposed cohorts; initial dose expansion and longer follow up on dose escalation data expected in 2026 -- BERKELEY, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for relapsed or refractory multiple myeloma (r/r MM).

seekingalpha.com

Mar 17

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety rivaling approved autologous products. CRBU trades near net cash value, implying the market assigns minimal value to its pipeline despite RMAT designation and promising Phase 1 results. Key risks include dilution, regulatory hurdles, and competition from in vivo CAR-T, but CRBU's CRISPR chRDNA editing and leadership provide strategic advantages.

defenseworld.net

Mar 16

Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference

Executives from Caribou Biosciences (NASDAQ: CRBU) outlined upcoming clinical, regulatory, and financing milestones for its allogeneic cell therapy pipeline during a discussion at the Leerink Global Healthcare Conference in Miami. Management focused on plans to advance its lead program, vispa-cel, into a pivotal study in second-line large B-cell lymphoma (LBCL) and provided updates on CB-011 in

zacks.com

Mar 5

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.39 per share a year ago.

globenewswire.com

Mar 5

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.

zacks.com

Feb 20

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.

Company Profile

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Sector

Healthcare

Industry

Biotechnology

Employees

147

IPO Date

2021-07-23

Beta

2.46

Websitecariboubio.com↗